Barclays raised the firm’s price target on Universal Health (UHS) to $259 from $257 and keeps an Overweight rating on the shares. The company’s core Q2 results missed estimates, but its EBITDA guidance was still raised $80M, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UHS:
- Universal Health Services Reports Strong Q2 2025 Results
- Universal Health downgraded to Underweight from Neutral at Cantor Fitzgerald
- Universal Health Services Balances Growth and Challenges in Earnings Call
- VOO ETF News, 7/29/2025
- Universal Health’s Mixed Performance and Future Challenges Lead to Hold Rating